Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Activation of eNOS activity in cisplatin-treated HUVEC cells assessed as increase in intracellular cGMP level at 30 uM preincubated with eNOS inhibitor, N(G)-nitro-L-arginine methyl ester followed by compound addition and further incubated for 15 mins by radioimmunoassay
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Activation of eNOS activity in cisplatin-treated HUVEC cells assessed as increase in intracellular cGMP level incubated for 15 mins by radioimmunoassay
Activation of eNOS activity in cisplatin-treated HUVEC cells assessed as increase in eNOS phosphorylation at Ser1177 residue at 30 uM preincubated with PI3K inhibitor, wortmannin followed by compound addition measured after 5 to 240 mins by Western blot analysis
Activation of eNOS activity in cisplatin-treated HUVEC cells assessed as increase in eNOS phosphorylation at Ser1177 residue at 30 uM preincubated with eNOS inhibitor, N(G)-nitro-L-arginine methyl ester followed by compound addition measured after 5 to 240 mins by Western blot analysis
Activation of eNOS activity in cisplatin-treated HUVEC cells assessed as increase in eNOS phosphorylation at Ser1177 residue at 30 uM measured after 5 to 60 mins by Western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of human eNOS using L-arginine as substrate assessed as reduction in NO production in the presence of NADPH by NO-hemoglobin capture assay
Assay data:6 Active, 11 Tested
Inhibition of human eNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr
Assay data:2 Active, 22 Tested
Enzyme Inhibition Assay from US Patent US10759791: "Mammalian and bacterial nitric oxide synthase inhibitors"
Assay data:24 Active, 21 Activity ≤ 1 µM, 24 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition Assay from US Patent US9212144: "2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition"
Assay data:13 Active, 12 Activity ≤ 1 µM, 16 Tested
Enzyme Inhibition Assay from US Patent US9090589: "Specific nNOS inhibitors for the therapy and prevention of human melanoma"
Assay data:8 Active, 8 Activity ≤ 1 µM, 9 Tested
Enzyme Assay from US Patent US8618286: "Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity"
Assay data:29 Active, 25 Activity ≤ 1 µM, 29 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Enzyme Assay from US Patent US8586620: "Substituted indole compounds having NOS inhibitory activity"
Assay data:49 Active, 18 Activity ≤ 1 µM, 52 Tested
Inhibitory Assay from Article 10.1021/bi1013479: "Role of zinc in isoform-selective inhibitor binding to neuronal nitric oxide synthase ."
Assay data:6 Active, 5 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
NOS Enzyme Inhibition Assay from Article 10.1038/nchembio.115: "Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase."
Assay data:15 Active, 14 Activity ≤ 1 µM, 15 Tested
Cell-Based NOS Transient Transfection Assay from Article 10.1021/jm900173b: "Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models."
Assay data:36 Active, 31 Activity ≤ 1 µM, 41 Tested
Inhibition Assay from US Patent US9951014: "Mammalian and bacterial nitric oxide synthase inhibitors"
Assay data:35 Active, 32 Activity ≤ 1 µM, 35 Tested
Inhibition Assay from US Patent US9732037: "2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors"
Assay data:21 Active, 20 Activity ≤ 1 µM, 21 Tested
Caco-2 Assay from US Patent US9878996: "2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase"
Assay data:13 Active, 9 Activity ≤ 1 µM, 14 Tested
Induction of eNOS phosphorylation in FFA-induced oxidatively stress human HepG2 cells by Western blot analysis relative to control
Assay data:7 Tested
Inhibition of human eNOS using L-argininge as substrate preincubated for 15 mins followed by NADPH addition and measured after 20 mins by OPA/NAC reagent based HPLC analysis
Assay data:2 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on